Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials.

Shankar-Hari, Manu; Estcourt, Lise; Harvala, Heli; Roberts, David; Menon, David K

Shankar-Hari, Manu; Estcourt, Lise; Harvala, Heli; Roberts, David; Menon, David K.

Shankar-Hari M; School of Immunology & Microbial Sciences, Kings College London, 5th Floor, Southwark Wing, London, SE1 9RT, UK. manu.shankar-hari@kcl.ac.uk.
Estcourt L; Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, 1st Floor, East Wing, St Thomas' Hospital, London, SE1 7EH, UK. manu.shankar-hari@kcl.ac.uk.
Harvala H; NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Oxford, OX3 9BQ, UK.
Roberts D; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Menon DK; National Microbiology Services, NHS Blood and Transplant, Charcot Road, Colindale, NW9 5BG, UK.

Crit Care ; 24(1): 449, 2020 07 20.

Article in English | MEDLINE | ID: covidwho-655605

Subject(s)

Coronavirus Infections/therapy; Pneumonia, Viral/therapy; COVID-19; Critical Illness; Humans; Immunization, Passive; Pandemics; Randomized Controlled Trials as Topic; COVID-19 Serotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Crit Care Year: 2020 Document Type: Article Affiliation country: S13054-020-03163-3

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google